Abstract
Introduction
Most, but not all (M cMillan et al., 1971; Harris, Walters & M cLendon, 1974; Leite & Carlini, 1974; W ikler, 1976; Com pton et al., 1990) animal studies report evidence of a rebound or withdrawal syndrome following high doses of delta-9-tetrahydrocannabinol (THC ). For example, Deneau & Kaymakcalan (1971) treated six rhesus monkeys over a 5-week span with up to 0.4 mg/kg of THC every 6 hours intravenously (i.v.) . Twelve hours after drug cessation, all monkeys experienced symptoms lasting approximately 5 days and characterized by aggressiveness, irritability, trem or, twitching, piloerection, anorexia, sexual excitem ent and bizarre behaviors that might be interpreted as hallucinations. Similarly, Fredericks & Benowitz (1980) injected four rhesus monkeys with 0.5 mg/kg of THC every 6 hours for 3 weeks, and observed tooth baring, eye contact and gross m otor activity when the drug was stopped. Possible withdrawal effects related to decreased food intake were also noted in two of three rhesus m onkeys treated for 10 days with a continuous i.v. infusion of THC (0.05 mg/kg per hour), a disrupted behavior which was reversed by readministration of THC (Beardsley, Balster & Harris, 1986) . Finally, in the only primate study using oral drug, two rhesus monkeys received 37.5 mg/kg of THC for 50 days, with both demonstrating increased aggressiveness after drug cessation, and one animal showing prolonged EEG desynchronization and behaviors that might indicate hallucinations (Stadnicki et al., 1974) .
There is also information from at least two types of hum an studies regarding the characteristics of a marijuana withdrawal syndrome. The ® rst, and potentially less conclusive, were anecdotal reports that included individual case histories, casual observations of regular users who were denied access to their drugs (Dilsaver, Leckrone & Greden, 1984; Rohr, Skowlund & Martin, 1989) , and clinical case reports (Fraser, 1949; Soueif, 1967; Bensus, 1971) . These highlighted the possible existence of a syndrom e, but did little to reassure the reader that the condition might not just have re¯ected general levels of stress, predisposing personality characteristics, additional psychopathology in the subjects, or the consequences of intoxication or withdrawal from other substances (Compton et al., 1990) .
The second type of human study incorporated more formal research protocols. Here, individuals with histories of marijuana use lived in a controlled environment where they were either encouraged to self-administer marijuana products, or were given pre-program med amounts of THC. Over a period of weeks subjects received the THC, access to other substances was controlled, and the potential developm ent of symptom s upon cessation of drug use was elvaluated (Williams et al., 1946; Cohen et al., 1976; Greenberg et al., 1976; Jones, Benowitz & Bachman, 1976; M endelson et al., 1976; Nowlan & Cohen, 1977; Georgotas & Zeidenberg, 1979; Mendelson et al., 1984) . Most studies agreed that a withdrawal syndrome was likely to begin within 24 hours of abstinence, peak in intensity on days 2± 4, and then diminish with few or no sym ptom s remaining by day 7 (Kielholz & Ladewig, 1970; Jones et al., 1976; M endelson et al., 1976; Georgotas & Zeidenberg, 1979) . M ost also agreed that subjects reported a decreased appetite, nausea, dem onstrated weight loss (Jones et al., 1976; Nowlan & Cohen, 1977; Georgotas & Zeidenberg, 1979) , showed sleeplessness which was reported to be associated with an increase in rapid eye movement sleep (Feinberg et al., 1975 (Feinberg et al., , 1976 Karacan et al., 1976) , and m any subjects evidenced either irritability or hyperactivity (Fraser, 1949; Jones et al., 1976; Nowlan & Cohen, 1977; Georgotas & Zeidenberg, 1979) . Some researchers reported evidence of a trem or or muscle twitching and sweating during withdrawal (Kielholz & Ladewig, 1970; Jones et al., 1976) . Additional symptoms that have been noted include increases in body temperature and salivary output (Jones et al., 1976) . In only one of these studies (Jones et al., 1976) did the authors attempt to document that the symptoms associated with a potential withdrawal were decreased by the administration of THC.
In summ ary, both anim al and human research indicate that sym ptom s consistent with a m arijuana withdrawal syndrome are observed following acute abstinence after receiving relatively high doses of marijuana. Most com plaints included restlessness, irritability, insom nia and decreases in appetite. As described by Jones (1983) these symptoms resembled what could be expected following withdrawal associated with m odest doses of alcohol or other brain depressants or opiates (Schuckit, 1995) . W hile it appears that a marijuana withdrawal syndrome can be produced in a laboratory setting, it is unclear from these data how frequently these symptoms are observed in a general population with a selfregulated pattern of drug use. The present paper utilizes data generated from face-to-face interviews with a large sample of alcohol-dependent individuals, their families and controls in order to evaluate the prevalence and possible clinical relevance of a m arijuana withdrawal syndrome.
M ethods
The data reported here were generated through the Collaborative Study on the Genetics of Alcoholism (COGA), an ongoing pedigree study of alcohol-dependent m en and wom en. The 5611 interviews used here were generated from faceto-face sessions carried out between January, 1991 and M arch, 1995, and included 758 alcohol-dependent probands (177 women) , 4064 ® rst-degree and extended relatives of these probands (2430 women), as well as 789 subjects from control families (405 women). The interviews were administered by staff at the six C OGA centers in San Diego, St Louis, Iowa C ity, Farmington, New York and Indianapolis.
The original alcohol-dependent probands represent a consecutive series of inpatients, out-patients and aftercare program participants in substance use disorder programs in the six cities. All probands (but not necessarily their relatives or controls) m et criteria for alcohol dependence as de® ned by DSM -III-R (Am erican Psychiatric Association, 1987), as well as de® nite alcoholism as de® ned by Feighner et al. (1972) . Potential probands were excluded if they did not speak English or had a history of repeated i.v. drug use, and only subjects whose nuclear family had ® ve or more individuals available for evaluation were included. No subject was excluded from the study because of any additional DSM -III-R Axis I or Axis II disorder. Control families were selected through a variety of mechanisms across the six sites including a random survey of young men at a university, individuals entering care for non-substance-related disorders, through the use of drivers' license records and via advertising.
Inform ed consent was obtained to carry out evaluations with the Sem i-Structured A ssessm ent for the G enetics of A lcoholism (SSAG A ) interview, which was given by trained personnel with established high levels of reliability (B ucholz et al., 1994) . D eveloped from portions of already existing structured interviews (Coryell, C loninger & R eich, 1978; Endicott & Spitzer, 1978; Robins et al., 19 85; R obins et al., 1988; Spitzer et al., 1992) , the SSAG A system atically reviews m ultiple diagnostic system s for 17 A xis I disorders, the antisocial personality disorder (ASPD ) and psychotic symptom s relevant to DSM -III-R.
Separate SSAGA sections were used to elicit information on demography, psychiatric histories, alcohol and drug use patterns, as well as problems associated with substance intake. The drug use and problem sections for all subjects included a query regarding the life-time history of ever having used marijuana, hashish or other cannabinoids, gathering more detailed information from individuals who had used these substances at least 21 times in any year. A positive response to that frequency of use resulted in a series of questions relating to ages of use, periods of abstinence, as well as information regarding areas of potential cannabis-related problems for abuse or dependence. For individuals who had taken other drugs of abuse, similar relevant information was gathered (Schuckit, 1995) .
In the present analyses the sam ple was broken down into groups based on the history of exposure to m arijuana and evidence of a potential m arijuana withdrawal syndrome. Thus, Group 1 included 2300 subjects (41.0%) who denied ever having used m arijuana, Group 2 comprised the 1576 (28.1%) who admitted to using marijuana but only 20 or fewer times in any single year, and Groups 3 and 4 related to the 1735 (30.9%) m en and women who had used m arijuana on 21 or more occasions in a single year. This included the 270 individuals in Group 4 (4.8% of the 5611 interviewed subjects and 15.6% of the 1735 more frequent users) who reported having had two or m ore marijuana withdrawal sym ptoms clustering together, and 1465 people (26.1% of the total) who used m arijuana at this frequency but denied any clustering of possible withdrawal symptoms (Group 3).
The diagnosis of possible m arijuana withdrawal was based on the self-report of any of the seven sym ptom s suggested to be relevant to a m arijuana withdrawal syndrom e in the literature (Williams et al., 1946; Cohen et al., 1976; Greenberg et al., 1976; Jones et al., 1976; M endelson et al., 1976; Nowlan & Cohen, 1977; Georgotas & Zeidenberg, 1979) . These included feeling nervous, tense, restless or irritable; having problem s sleeping; developing a twitch or trem or; having sweats or a fever; experiencing nausea or vomiting; having had diarrhea or stomach aches; or reporting an appetite change associated with cutting down or stopping m arijuana or other cannabinoid use following a period of regular intake. Because the literature is not clear on the appropriate threshold for establishing a diagnosis, it was a priori required that two or more of these symptoms had clustered together during at least one reported withdrawal. DSM -IV requires two sym ptom s for a withdrawal syndrome from alcohol, sedative± hypnotics, amphetamines and cocaine, although thresholds of three or four items are required for withdrawal from opiates or nicotine (Am erican Psychiatric Association, 1994).
The analyses presented in this paper explore the characteristics of subjects who reported a m arijuana withdrawal syndrome (Group 4), contrasting these with repeat users who did not report a clustering of withdrawal phenomena when they stopped or cut back on cannabinoid use (Group 3). A c 2 statistic was used for a comparison of categorical data, while a Student' s t-test was invoked for a comparison of m eans. In order to place the Group 3 versus 4 comparisons in perspective, data are also offered regarding Table 1 relates the self-report for each of the seven potential withdrawal symptoms for the more frequent cannabis users. The ® rst data columns offer information on subjects from Groups 3 and 4 com bined, regardless of the total number of possible withdrawal symptoms that they reported, and independent of whether symptoms ever clustered together. The second set of data columns focuses only on the 270 Group 4 individuals who reported two or more symptoms of withdrawal clustering together. Using either approach, the m arijuana-related sym ptoms most likely to be reported by either group after stopping use were nervousness, sleep disturbances or appetite change. The symptoms of trem or, sweating, diarrhea or nausea were observed relatively infrequently. Tables 2 and 3 describe the demographic and substance related characteristics of the subjects in the four groups. While not shown in the tables, the ages across Groups 1 to 4 were 48.1 ( 6 16.56), 35.7 ( 6 11.42), 32.7 ( 6 7.53) and 32.0 ( 6 7.31) years, respectively, with no signi® cant differences between Groups 3 and 4 (t 5 1.65; df 5 1,733; p 5 0.12). The mean ( 6 SD) for years of com pleted schooling were 12.9 ( 6 2.62), 13.1 ( 6 2.34), 12.7 ( 6 2.10), and 12.2 ( 6 2.08) years, with the latter two groups being signi® cantly different (t 5 3.34; df 5 1,733; p , 0.001).
As shown in Table 2 , compared with Group 3, Group 4 subjects were more likely to have been m ale alcohol-dependent probands, and fewer were em ployed full-time. Also, the proportion of m arried subjects was signi® cantly lower in Group 4 (c more likely to have ful® lled criteria for dependence on other drugs and to be ASPD. Group 4 subjects were also more likely than those in Group 3 to have been treated for alcohol or other substance dependence, but were not more likely to have close relatives with substance use disorders or ASPD . Thus, while the data indicate consistent differences between Groups 3 and 4 subjects on m easures of the intensity of use of marijuana, those in Group 4 were also m ore likely to have used and to have become dependent on alcohol and drugs other than m arijuana. To test the possibility that reports of m arijuana withdrawal might have re¯ected the in¯uence of other substances, a logistic regression analysis was performed on the subjects in Groups 3 and 4. Clustering of two or m ore withdrawal symptom s (i.e. Group 4 vs. Group 3 membership) was the dependent variable, while the independent variables included two measures of m arijuana use (the longest period of continuous daily m arijuana use and the number of times of marijuana use), a diagnosis of ASPD and the presence or absence of a diagnosis of dependence on alcohol or the four other categories of drugs in Table 4 . These eight predictor variables yielded a m odel that signi® cantly described marijuana withdrawal (c 2 5 172.25; df 5 8; p 5 0.0001; Hosmer & Lemeshow GOF 5 8.60; p 5 0.38). Within this m odel, the longest period of daily marijuana use, the number of times this drug was taken, sedative/hypnotic dependence, alcohol dependence and ASPD added signi® cant unique contributions to predicting a m arijuana withdrawal syndrome. The largest odds ratios, indicating the increased likelihood of reporting marijuana withdrawal as a function of the presence of the predictor, were observed for sedative/hypnotic dependence (2.34) and alcohol dependence (2.03). However, even though the odds ratio for the longest period of daily use was only 1.005, it is important to remember that this is a continuous variable and the unit is each month of use. The increase in the value of this predictor by a single unit, 1 m onth, has a far less impact on the occurrence of marijuana withdrawal than the increase by a single unit (i.e. from ª noº to ª yesº ) of a categorical variable such as sedative or alcohol dependence, but because of the large number of m onths of use this variable was an important predictor. The sam e explanation applies to the low odds ratio (1.001) of the second continuous variable, the num ber of tim es of marijuana use. Several additional steps were taken to probe for evidence of a marijuana withdrawal syndrom e even after controlling for the impact of other drugs. The ® rst was to evaluate if marijuana use patterns still contributed to Group 4 m em bership when additional withdrawal phenomena to other drugs were considered. Therefore, a second logistic regression was carried out, but in this case substituting a diagnosis of withdrawal rather than a diagnosis of dependence on each of the other drugs. The results were quite sim ilar to those displayed in Table 4 (c 2 5 202.3; df 5 8; p 5 0.0001; GOF 5 6.29; p 5 0.61). Reported withdrawal syndrom es from sedatives/hypnotics and alcohol had signi® cant unique contributions to predicting Group 4 mem bership within this m odel. Importantly, even after taking into account withdrawal from those drugs, both assessm ents of marijuana use (ª longest period of daily useº and ª number of tim es of useº ) still signi® cantly contributed to Group 4 member- ship, with the same odds ratios as reported earlier. Another attempt to probe for the validity of self-reports of a marijuana withdrawal syndrome was to identify a subgroup among the 270 individuals in Group 4 who reported marijuana withdrawal but who did not meet criteria for dependence on any drug other than marijuana. Thus, the marijuana-related syndrome could be studied without possible contamination by the impact of other drugs. Unfortunately, 237 of the 270 men and women in this category m et criteria for alcohol dependence either alone or in the context of other drug dependencies, and 15 of the remaining 33 individuals m et criteria for dependence on sedative/hypnotics, opiates or cocaine. Only 10 m en and eight women reported a marijuana withdrawal syndrome in the absence of dependencies on other drugs. Although this sam ple is too small to generate meaningful conclusions, it is worth mentioning that the most frequently observed withdrawal symptom s for these 18 subjects (ª nervous, tense, restlessnessº , ª sleep disturbanceº and ª appetite changeº ) were the same as those reported by the frequent users of Group 3 and 4 reported in Table 1 .
Finally, it was hypothesized that if Group 4 subjects were accurately reporting a marijuana withdrawal syndrome there should be a relationship between the level of restrictiveness of the diagnostic criteria and m easures of the use of marijuana. Thus, the patterns of m arijuana use associated with a threshold of three of the seven possible withdrawal items in Table 1 , and then four of the seven possible items were evaluated. Since the structured interview cut off the number of marijuana uses at 999 times during life- However, when the group with two symptoms was compared to those with four, the difference was signi® cant (t 5 1.71; df 5 197; p 5 0.045).
This result suggests that in Group 4 subjects an increase in the number of withdrawal symptoms that clustered together was associated with an increase in the length of time of daily marijuana use, but the effect was not very strong.
While the major focus of this work was to identify the prevalence and characteristics associated with the self-report of m arijuana withdrawal among cannabinoid users, the data gave interesting information on the characteristics of users overall. To analyze this issue more closely, the non-users and the less-than-21-times per year users were combined (Group 1 1 2) and then compared with the more frequent marijuana users (Group 3 1 4) . Statistical evaluation revealed that Group (1 1 2) differed signi® cantly from Group (3 1 4) in almost every variable listed in Tables 2 and 3 
Discussion
Both anim al and hum an research indicate that under some circumstances withdrawal symptoms develop following exposure to high levels of marijuana. However, after reviewing animal and human studies, it is not possible to either establish the prevalence or describe the pro® le of the more usual marijuana withdrawal phenom ena in a non-drug clinic population. To approach this problem, the present study used data from a large cohort of individuals and addressed three major questions: (1) how prevalent was a marijuana withdrawal syndrom e in a population not selected because of seeking treatment for marijuana-related problems? (2) what were the characteristics of the usual withdrawal syndrom e? and (3) could marijuana withdrawal be disentangled from the intoxication or the withdrawal sym ptom s of alcohol or other drugs?
In the present analyses, the threshold for a withdrawal syndrom e was set as two of seven potential items, a ratio chosen as being representative of most withdrawal syndrom es in DSM-IV. Using this approach only 4.8% of the total sample, but 15.6% of the m ore frequent m arijuana users, reported ever experiencing at least one withdrawal syndrom e related to marijuana. The clinical sym ptom s reported were usually limited to feelings of nervousness, sleep disturbance or a change in appetite. This was consistent with the withdrawal pro® le reported by a small subsam ple of 18 subjects who were never dependent on drugs other than marijuana. There was no evidence that any individuals received treatm ent for their withdrawal, and none offered a history of signi® cant morbidity associated with the syndrome. There were several types of indication that what was being reported as a marijuana withdrawal syndrome might have been accurate. First, regarding intensity of use Group 4 subjects reported the highest average number of uses of m arijuana, and gave a history of alm ost 70 m onths of daily or nearly daily self-adm inistration of this drug. M ore than eight of 10 of the subjects in Group 4 reported ever having stayed high from marijuana for an entire day at a tim e. On each of these m easures, the Group 4 subjects who reported at least one withdrawal syndrom e in the past had signi® cantly higher intensities of intake than Group 3 men and wom en. A second indication of the probable validity of the selfreports of a withdrawal syndrome com es from the two logistic regression analyses where the two measures of intensity of use (the number of times of marijuana intake and the longest period of daily use) remained robust predictors of Group 4 membership even after conside ring the potential impact of the diagnoses of dependence or of withdrawal syndromes on drugs other than m arijuana. Finally, there was at least a trend whereby those individuals reporting a larger number of withdrawal symptoms were likely to have reported longer periods of daily use.
Of course, the present results must be considered in light of the methodologies employed. Unfortunately, the manner in which the data were collected did not allow for a direct analysis of the number of tim es marijuana was taken per m onth as a predictor of a withdrawal phenomenon. Thus, it is possible that had we been able to isolate a group with a larger number of administrations per day for an extended period of tim e, the intensity of the withdrawal syndrome might have been higher. At the very least, the present data indicate that som e level of withdrawal can occur after heavy marijuana consumption, even in a population not originally identi® ed because they sought help for a m arijuana-related problem .
In addition, all information was generated from retrospective self-reports, and many subjects had experience with multiple drugs. Thus, it is possible that a prospective study might have identi® ed a larger proportion of subjects with withdrawal symptoms, or m ight have identi® ed a different pattern of withdrawal phenomena. On the other hand, of the 270 Group 4 subjects who reported withdrawal, only 18 individuals did so in the absence of dependence on drugs other than m arijuana. Thus, it is not possible from the present data to de® nitively establish that the withdrawal symptoms reported did not sim ply re¯ect symptoms related to actual withdrawal from alcohol, sedative/hypnotics or opiates. It is also possible that the experience of intoxication and potential withdrawal symptom s from these other classes of drugs might have facilitated the developm ent of withdrawal symptoms related to marijuana.
Gathered from a very large sam ple of carefully interviewed subjects, the data suggest that some level of m arijuana withdrawal not only occurs in the experimental literature, but is also experienced under realistic conditions of a self-chosen pattern of drug use. These data indicate that it may be helpful for clinicians to reassure their patients with a history of heavy m arijuana use, that restlessness, insomnia and lack of appetite could be re¯ections of withdrawal discomfort, that these symptoms m ight impact on their desire to return to use of the substance, but are not likely to progress to a m ore severe syndrome that requires acute medical intervention. 
